精准疾病管理：长期COVID慢性肺损伤的预后生物标志物

IF 4.3 3区医学 Q1 RESPIRATORY SYSTEM

ERJ Open Research Pub Date : 2024-12-02 eCollection Date: 2024-11-01 DOI:10.1183/23120541.00647-2024

Adrian Oo, Justin Jang Hann Chu

引用次数: 0

摘要

早期发现潜在的严重疾病进展有助于实施相关的精确疾病管理战略。MMP-7是COVID - 19长期持续性肺损伤的可靠预后生物标志物，应考虑用于临床。https://bit.ly/3Ccxozg。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Precision disease management: prognostic biomarker for chronic lung damage in long COVID.

Early detection of potential severe disease progression facilitates implementation of relevant precise disease management strategies. MMP-7 is a reliable prognostic biomarker for long COVID persistent lung damage that should be considered for clinical use. https://bit.ly/3Ccxozg.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

ERJ Open Research Medicine-Pulmonary and Respiratory Medicine

CiteScore

6.20

自引率

4.30%

发文量

273

审稿时长

8 weeks

期刊介绍： ERJ Open Research is a fully open access original research journal, published online by the European Respiratory Society. The journal aims to publish high-quality work in all fields of respiratory science and medicine, covering basic science, clinical translational science and clinical medicine. The journal was created to help fulfil the ERS objective to disseminate scientific and educational material to its members and to the medical community, but also to provide researchers with an affordable open access specialty journal in which to publish their work.